Editas Medicine Inc (GB:0IFK)
LSE:0IFK
UK Market

Editas Medicine Stock Analysis & Ratings

GB:0IFK Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$10.01
VolumeN/A
Average Volume (3M)1.10K
Market Cap$687.10M
P/E RatioN/A
Beta1.86
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score1
EPS (TTM)0.00


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:0IFK FAQ

What was Editas Medicine’s price range in the past 12 months?
Editas Medicine lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Editas Medicine’s market cap?
    Editas Medicine’s market cap is $687.10M.
      What is Editas Medicine’s price target?
      The average price target for Editas Medicine is $22.27. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $40.00 ,the lowest forecast is $8.00. The average price target represents 122.48% Increase from the current price of $10.01.
        What do analysts say about Editas Medicine?
        Editas Medicine’s analyst rating consensus is a ‘Hold. This is based on the ratings of 12 Wall Streets Analysts.
          When is Editas Medicine’s upcoming earnings report date?
          Editas Medicine’s upcoming earnings report date is Aug 10, 2022 which is in 75 days.
            How were Editas Medicine’s earnings last quarter?
            Editas Medicine released its earnings results on May 04, 2022. The company reported -$0.74 earnings per share for the quarter, beating the consensus estimate of -$0.782 by $0.042.
              Is Editas Medicine overvalued?
              According to Wall Street analysts Editas Medicine’s price is currently Undervalued.
                Does Editas Medicine pay dividends?
                Editas Medicine does not currently pay dividends.
                What is Editas Medicine’s EPS estimate?
                Editas Medicine’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Editas Medicine have?
                Editas Medicine has 68,640,000 shares outstanding.
                  What happened to Editas Medicine’s price movement after its last earnings report?
                  Editas Medicine reported an EPS of -$0.74 in its last earnings report, beating expectations of -$0.782. Following the earnings report the stock price went down -0.789%.
                    Which hedge fund is a major shareholder of Editas Medicine?
                    Among the largest hedge funds holding Editas Medicine’s share is ARK Investment Management LLC. It holds Editas Medicine’s shares valued at 15M.

                      ---

                      Editas Medicine Stock Analysis

                      Smart Score
                      1
                      Underperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $22.27
                      ▲(122.48% Upside)
                      Hold
                      The Editas Medicine stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Editas Medicine Inc

                      Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Adverum Biotechnologies
                      Sangamo Biosciences
                      Bluebird Bio
                      Intellia Therapeutics
                      Crispr Therapeutics AG

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis